Bio-Medical Sciences Department, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, 9112001 Jerusalem, Israel.
Fritz Haber Research Centre, Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel.
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7694-7699. doi: 10.1073/pnas.1804214115. Epub 2018 Jul 5.
Every individual cancer develops and grows in its own specific way, giving rise to a recognized need for the development of personalized cancer diagnostics. This suggested that the identification of patient-specific oncogene markers would be an effective diagnostics approach. However, tumors that are classified as similar according to the expression levels of certain oncogenes can eventually demonstrate divergent responses to treatment. This implies that the information gained from the identification of tumor-specific biomarkers is still not sufficient. We present a method to quantitatively transform heterogeneous big cancer data to patient-specific transcription networks. These networks characterize the unbalanced molecular processes that deviate the tissue from the normal state. We study a number of datasets spanning five different cancer types, aiming to capture the extensive interpatient heterogeneity that exists within a specific cancer type as well as between cancers of different origins. We show that a relatively small number of altered molecular processes suffices to accurately characterize over 500 tumors, showing extreme compaction of the data. Every patient is characterized by a small specific subset of unbalanced processes. We validate the result by verifying that the processes identified characterize other cancer patients as well. We show that different patients may display similar oncogene expression levels, albeit carrying biologically distinct tumors that harbor different sets of unbalanced molecular processes. Thus, tumors may be inaccurately classified and addressed as similar. These findings highlight the need to expand the notion of tumor-specific oncogenic biomarkers to patient-specific, comprehensive transcriptional networks for improved patient-tailored diagnostics.
每个癌症个体都是以其独特的方式发展和生长的,这就产生了对开发个性化癌症诊断方法的需求。这表明,鉴定患者特异性致癌基因标志物将是一种有效的诊断方法。然而,根据某些致癌基因的表达水平分类为相似的肿瘤最终可能对治疗产生不同的反应。这意味着从鉴定肿瘤特异性生物标志物中获得的信息仍然不够。我们提出了一种方法,可以将异质的大型癌症数据定量转化为患者特异性转录网络。这些网络描述了使组织偏离正常状态的不平衡分子过程。我们研究了跨越五个不同癌症类型的多个数据集,旨在捕获特定癌症类型内以及不同起源的癌症之间存在的广泛的患者间异质性。我们表明,相对较少数量的改变的分子过程足以准确地描述超过 500 个肿瘤,从而显示出数据的极度紧缩。每个患者都由一小部分不平衡的过程所特征化。我们通过验证所鉴定的过程也能描述其他癌症患者来验证结果。我们表明,不同的患者可能表现出相似的致癌基因表达水平,尽管携带具有不同的不平衡分子过程集的生物学上不同的肿瘤。因此,肿瘤可能被不准确地分类和归类为相似的。这些发现强调了需要将肿瘤特异性致癌生物标志物的概念扩展到患者特异性、全面的转录网络,以实现更好的针对患者的诊断。